Eloralintide vs. Cagrilintide Amylin-based peptides for appetite regulation and weight management Eloralintide: Eloralintide is an investigational, long-acting amylin receptor agonist being developed for obesity and weight management. Amylin is a hormone naturally released alongside insulin after eating. It helps regulate appetite, satiety, and gastric emptying. Potential benefits: Appetite suppression: Activates amylin receptors involved in hunger and satiety signaling. Weight reduction: Early clinical research supports its potential to reduce body weight. Increased satiety: May help individuals feel satisfied with smaller meals. Reduced food intake: Targets central appetite pathways that influence eating behavior. Slower gastric emptying: Amylin signaling can delay stomach emptying, although the magnitude of this effect with eloralintide requires further study. Potential combination therapy: May complement incretin-based treatments through a different hormonal pathway. Important distinction: Eloralintide’s weight-loss potential is supported by emerging research, but improvements in insulin sensitivity, cardiovascular outcomes, and long-term weight maintenance have not been conclusively established. Common side effects: Nausea, fatigue, gastrointestinal discomfort, vomiting, constipation, diarrhea Cagrilintide: Cagrilintide is a long-acting amylin analogue being investigated for obesity and weight management. It mimics the effects of amylin, a hormone naturally secreted by pancreatic beta cells alongside insulin. Unlike GLP-1 medications, cagrilintide primarily targets the amylin signaling system, offering a different pathway for appetite regulation. Benefits: Appetite suppression: Reduces hunger signaling and promotes earlier feelings of fullness. Increased satiety: Helps prolong the sensation of fullness after eating. Weight reduction: Clinical trials have demonstrated meaningful reductions in body weight. Reduced caloric intake: Helps decrease overall food consumption through appetite regulation.